Researchers at the National Cancer Institute (NCI) seek licensing for an improved cell line called Tni-FNL which is capable of high level expression of heterologous proteins using baculovirus expression systems.
Researchers from NCI and Rudgers University developed methods of detecting abnormal cells in a sample using the spatial position of one or more genes within the nucleus of a cell, as well as a kit for detecting abnormal cells using such methods. The invention also provides methods of identifying gene markers for abnormal cells using the spatial position of one or more genes within the nucleus of a cell.
The National Cancer Institute seeks parties interested in collaborative research to co-develop diagnostic methods for detection of cancer using spatial genome organization.
Researchers at the National Institute on Drug Abuse (NIDA) seek licensing or co-development of a Human Research Information System (HuRIS) software that automates all major functions of a clinical-research entity. The system is designed for commercial healthcare providers, community treatment centers, and clinical research facilities.
Researchers at the National Institute on Drug Abuse (NIDA) seek licensing or co-development of a mobile health technology that monitors and predicts a user’s psychological status in order to deliver an automated intervention when needed.
Researchers at the National Institutes of Health Clinical Center (NIHCC) and Northern Arizona University (NAU) seek licensing and/or co-development research collaborations for a wearable, pediatric, robotic exoskeleton that facilitates knee extension during walking to provide motorized movement assistance and training through the gait cycle. The Robotic Exoskeleton is specifically designed for therapy of crouch gait in children with cerebral palsy (CP). The design is a customizable human-machine interface that allows an individualized assistance protocol to help preserve and enhance muscle strength and control. Early clinical results from this intervention appear promising for a condition having few effective long-term interventions.
Ultrasound-based cancer screening and biopsy imaging technique are a critical clinical need. Ultrasound based biopsy imaging can provide a real-time modality for lower cost that is comparable to, or complimentary to MRI imaging. Researchers at the NIH Clinical Center seek licensing and/or co-development research collaborations for Tissue Characterization with Acoustic Wave Tomosynthesis.
Device is used to guide a stream of oxygen or carbon dioxide over a dish of cells during fluorescence microscopy. Invention includes the 3D printing software to create the device. The device makes it possible to easily provide a steady source of oxygen or carbon dioxide to cells while operating a fluorescent microscope to oxidize fluorophores for later visualization in electron microscopy. NCI seeks commercial partners to license this technology.
The NCI seeks licensees or co-development partners for this technology, which describes compositions, methods and kits for identifying, characterizing biomolecules expressed in a sample that are associated with the presence, the development, or progression of cancer.
The National Cancer Institute''s Laboratory of Cell Biology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize bodipy conjugated tyrosine kinase inhibitors that are currently used in the clinic for the treatment of CML or gastric cancers.
Researchers at the National Institute on Drug Abuse (NIDA) have developed an apparatus that is used to image rodents while they are awake. The biological effects of agents on the rats can be imaged (via MRI for instance) in real time over a prolonged period of time.
Available for licensing is computer software for the automated generation of density maps of macromolecular structures from a series of 2D digital micrographs of frozen hydrated specimens collected using an electron microscope equipped with an ultra-cooled computerized stage.
The National Cancer Institute seeks licensees or research collaborators to develop and commercialize transgenic mice having immunocompetent rat growth hormone-firefly Luciferase-enhanced green fluorescent protein.